1. Epizyme’s Tazverik (tazemetostat) Receives the US FDA’s Accelerated Approval as the First Therapy for Epithelioid Sarcoma Published: Jan 23, 2020 | Tags: Epizyme, Tazverik, tazemetostat, Receives, US, FDA, Accelerated Approval, […]readmore
Tags : PhoreMost
Shots: The companies collaborated to identify targets for Otsuka’s therapeutics discovery programmes by leveraging PhoreMost’s expertise and next-generation phenotypic screening platform, SITESEEKER Otsuka will validate the novel targets identified in […]readmore
Nektar Therapeutics Signs a Clinical Trial Collaboration with Bristol-Myers Squibb Published: Jan 10, 2020 | Tags: Nektar Therapeutics, Signs, Clinical Trial, Collaboration, Bristol-Myers Squibb 2. Eli Lilly to Acquire Dermira for […]readmore
Shots: PhoreMost to receive upfront and research funding plus milestones and will utilize its expertise and phenotypic screening platform, SITESEEKER for the targets identified by BI and will be further […]readmore
Shots: The agreement collaborates C4XD’s Taxonomy3 (target identification platform) with PhoreMost’s SITESEEKER (screening platform) to accelerate drug discovery initially focusing on Parkinson’s disease with expected profit sharing by both the […]readmore